Your browser doesn't support javascript.
Advances in developing small molecule SARS 3CLpro inhibitors as potential remedy for corona virus infection.
Konwar, Manashjyoti; Sarma, Diganta.
  • Konwar M; Department of Chemistry, Dibrugarh University, Dibrugarh, 786004, Assam, India.
  • Sarma D; Department of Chemistry, Dibru College, Dibrugarh, 786003, Assam, India.
Tetrahedron ; 77: 131761, 2021 Jan 01.
Article in English | MEDLINE | ID: covidwho-1279699
ABSTRACT
Originated in China, coronavirus disease 2019 (COVID-19)- the highly contagious and fatal respiratory disease caused by SARS-CoV-2 has already infected more than 29 million people worldwide with a mortality rate of 3.15% (according to World Health Organization's (WHO's) report, September 2020) and the number is exponentially increasing with no remedy whatsoever discovered till date. But it is not the first time this infectious viral disease has appeared, in 2002 SARS-CoV infected more than 8000 individuals of which 9.6% patients died and in 2012 approximately 35% of MERS-CoV infected patients have died. Literature reports indicate that a chymotripsin-like cystein protease (3CLpro) is responsible for the replication of the virus inside the host cell. Therefore, design and synthesis of 3CLpro inhibitor molecules play a great impact in drug development against this COVID-19 pandemic. In this review, we are discussing the anti-SARS effect of some small molecule 3CLpro inhibitors with their various binding modes of interactions to the target protein.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Tetrahedron Year: 2021 Document Type: Article Affiliation country: J.tet.2020.131761

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Tetrahedron Year: 2021 Document Type: Article Affiliation country: J.tet.2020.131761